The QualityStocks Daily Monday, July 15th, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (CAPR) +93.48%

StreetInsider (TRNX) +33.30%

OTCtipReporter (SGBX) +31.68%

The QualityStocks Daily Stock List

Western Uranium & Vanadium Corp. (WSTRF)

Streetwise Reports, Zacks, Energy and Capital, YCharts, Barchart, Investor Intel, Stockwatch, Dividend Investor, Trading View, Marketbeat, Junior Mining Network, GlobeNewswire, Stockhouse, Proactive Investors, Morningstar, Market Screener, Business Insider, The Street, Nasdaq, Last10k, and MarketWatch reported beforehand on Western Uranium & Vanadium Corp. (WSTRF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Western Uranium & Vanadium Corp. is a uranium and vanadium conventional mining company. It concentrates on low cost near-term production of uranium and vanadium in the western U.S., as well as the development and application of ablation mining technology. Ablation Mining Technology (AMT) is a proprietary process that improves efficiency and decreases costs for sandstone hosted deposits. Western Uranium & Vanadium has offices in Toronto, Ontario and Nucla, Colorado.

The Company is among the largest U.S. Uranium and Vanadium in-situ resource holders. It has a total uranium resource of 70,000,000 lbs. +/- and a total vanadium resource of 35,000,000 lbs. +/- grading between 1.4-2.2 percent. Its near-term production strategy includes centering on previously producing mines for low CAPEX (capital expenditure|), existing infrastructure & permitting. Western Uranium & Vanadium’s strategy also includes defining and developing a high-grade vanadium resource at the Sunday Mine Complex (SMC). Furthermore, the Company’s strategy is to deliver SMC ore samples to many potential customers and joint venture (JV) partners, and baseload SMC production with a vanadium ore concentrate agreement.

Moreover, its strategy is to pursue vanadium development at the Sage Mine Project. It will also work to pursue uranium contracts and development at prices above present price levels.

Last month, Western Uranium & Vanadium announced commencement of the Sunday Mine Complex Vanadium Project. On June 18, 2019, the Sunday Mine and the St. Jude Mine portals were opened. The Company’s Chief Geologist Dr. Kaiwen Wu increased the scope of the project to also include the Carnation Mine. Thus, this will be the third of the five individual permitted and developed mines.

Historical geological and mining data analysis of the sandstone hosted deposits has provided more than a half dozen initial target locations for sampling to identify high grade vanadium zones. Following bulk sampling, vanadium ore samples will be delivered to prospective customers worldwide.

Western Uranium & Vanadium Corp. (WSTRF), closed Monday's trading session at $0.8449, off by 8.4417%, on 67,619 volume with 48 trades. The average volume for the last 3 months is 25,423 and the stock's 52-week low/high is $0.000099999/$0.400000005.

chart

Cosmos Holdings, Inc. (COSM)

Real Investment Advice, Tech Know Bits, Proactive Investors, Stockwatch, Stockopedia, and Stockhouse reported earlier on Cosmos Holdings, Inc. (COSM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Sailfish Royalty Corp. engages in the acquisition of gold and silver royalty and streaming agreements in the Americas. The Company is backed by Wexford Capital LP, a well-funded investor that was part of the creation of Viper Energy Partners LP (Nasdaq: VNOM), a foremost energy royalty company with a US$4.4 billion market cap. Sailfish Royalty is headquartered in Road Town, British Virgin Islands (BVI). The Company’s shares trade on the OTC Markets Group’s OTCQX.

Sailfish has a straightforward business model. It receives the right to purchase a portion of the gold and/or silver produced from a mine at a fixed price or discount to spot. It receives a portion of the revenue generated from a mine. Sailfish then sells the metal at spot.

Regarding its existing portfolio, Sailfish Royalty has two cornerstone royalty assets on advanced stage projects in the Americas. One is the restructured San Albino Gold Stream and the other is the Tocantinzinho Royalty (TZ Royalty).

The San Albino Gold Stream is a gold stream equivalent to a 3 percent NSR on the San Albino project and the present AOI and a 2 percent NSR on the rest of the 138 sq. km area surrounding the AOI. The San Albino PEA indicates a high-grade, low capital expenditure operation with low all-in sustaining costs. The permit to build and operate (up to 500tpd) was received in September of 2017. The restructuring of the San Albino gold stream added additional assets to Sailfish Royalty’s portfolio.

Pertaining to the TZ Royalty, there is a 3.5 percent NSR royalty (the operator has the right to reduce to a 1.5 percent NSR). It is an open pit gold project positioned in the prolific Tapajos district of northern Brazil. Expected production is 170,000 oz. gold over 10 years.

Royalty cash flow has begun from El Compas (El Compas, Zacatecas, Mexico - 1.5 percent NSR on permitted gold and silver project). It is expected to grow as San Albino and Tocantinzinho come online. Sailfish Royalty intends to aggressively increase its portfolio and become a yield-focused Company through paying dividends to its shareholders. Sailfish Royalty’s intention is to pay out up to 90 percent of the cash flow it receives in the form of dividends to its shareholders.

Cosmos Holdings, Inc. (COSM), closed Monday's trading session at $3.15, off by 5.6886%, on 600 volume with 1 trade. The average volume for the last 3 months is 1,038 and the stock's 52-week low/high is $1.32599997/$15.3400001.

chart

MediPharm Labs Corp. (MEDIF)

CannabisFN, Investing News, New Cannabis Ventures, Small Cap Power, Street Register, Stockhouse, Midas Letter, Micro Small Cap, InvestorsHub, and Insider Financial reported previously on MediPharm Labs Corp. (MEDIF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

MediPharm Labs Corp. is a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation. It is the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. The Company primarily concentrates on producing pharma-grade cannabis oil and concentrates in Canada. Established in 2015, MediPharm Labs is based in Barrie, Ontario. The Company lists on the OTCQX.

MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm’s private label program is a high margin business for the Company. It procures dry cannabis flower and trim from its numerous product supply partners to produce cannabis oil concentrate products for resale internationally on a private label basis.

In essence, MediPharm Labs is a worldwide leader in premier quality, industrial-scale cannabinoid-based derivatives. In addition, the Company focuses on providing cannabis contract processing services to licensed producers and growers; supplying cannabis oil to companies for sale under its brand; and supplying raw materials and processing for the creation of market ready cannabis products.

MediPharm Labs delivers pure, safe and precisely dosable cannabis concentrates for private label advanced derivative products. It has state-of-the-art technology, cutting-edge proprietary methodologies, and is a leader in cannabis extraction and purification. It has highly scaled operations. By way of its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

In June, MediPharm Labs announced it successfully completed its first export shipment of medical cannabis concentrate into Australia to AusCann Group Holdings Ltd. Via its wholly-owned subsidiary, MediPharm Labs, Inc., it has become the first Canadian extraction-only company to publicly announce that it has received an export permit from Health Canada for the shipment of cannabis solid concentrate, under the new regulations, from Canada to Australia. Before the shipment, the Australian Government’s Office of Drug Control Section also issued an import permit.

Furthermore, in June, MediPharm Labs announced that MediPharm Labs, Inc. entered into purchase agreements to secure a considerable 9,000 KG of dried cannabis supply from manifold cultivators in the last three weeks in June. In addition to MediPharm Labs’ continuing procurement of cannabis biomass for existing contracts, this bulk purchase is expected to contribute to increased production for future sales and position MediPharm to meet the mandatory minimum monthly volume requirements to win new large white-label contracts.

MediPharm Labs Corp. (MEDIF), closed Monday's trading session at $3.5094, up 8.6502%, on 241,026 volume with 543 trades. The average volume for the last 3 months is 330,389 and the stock's 52-week low/high is $0.004999999/$0.220599994.

chart

AmeriCann, Inc. (ACAN)

NetworkNewsWire, Daily Marijuana Observer, OTC Markets, Trading View, Profit Confidential, MarketWatch, TipRanks, Insider Financial, Equities, Stockhouse, Market Screener, Financial Buzz, InvestorsHub, and Wallet Investor reported previously on AmeriCann, Inc. (ACAN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AmeriCann, Inc. designs, develops, and owns medical cannabis facilities to produce medical cannabis in the United States. The Company partners with local businesses to serve marijuana patients in their communities. It is developing state-of-the-art cultivation, processing and product manufacturing facilities. It utilizes greenhouse technology for cannabis cultivation and is designing GMP Certified cannabis extraction and product manufacturing infrastructure. OTCQB-listed, AmeriCann is based in Denver, Colorado.

AmeriCann, through a wholly-owned subsidiary, AmeriCann Brands, Inc., intends to secure licenses to cultivate cannabis and produce cannabis infused products. This includes beverages, edibles, topicals, vape cartridges, and concentrates. AmeriCann Brands, Inc. plans to operate a Marijuana Product Manufacturing business at the Massachusetts Cannabis Center with greater than 40,000 square feet of state-of-the art extraction and product manufacturing infrastructure.

AmeriCann’s goal is to serve cannabis patients and consumers through providing state-of-the-art facilities designed and constructed to produce high quality, consistent cannabis cultivated and processed in a controlled, secure, and sustainable environment.

Additionally, concerning its Real Estate Services, AmeriCann employs a proven strategy for identifying, acquiring and developing real estate specifically suited for cannabis operations. In addition, concerning Licensing Procurement, the Company has been contributory in winning cannabis licenses in competitive application processes across the country.

AmeriCann announced in the spring that construction was progressing fast and on schedule at its flagship project, the Massachusetts Cannabis Center (MCC). The MCC is undergoing development on a 52-acre parcel situated in Southeastern Massachusetts. The MCC project is permitted for 987,000 sq. ft. of cannabis cultivation and processing infrastructure for the existing medical cannabis and the newly emerging adult-use cannabis marketplace. Building 1 of the MCC, a 30,000 square foot cultivation and processing facility, is scheduled to be completed next month.

AmeriCann has a 15-year Joint Venture Partnership with Bask, Inc. Bask is an existing Massachusetts licensed vertically integrated cannabis operator. AmeriCann will receive a Revenue Participation Fee of 15 percent of Gross Revenue on all products produced and sold from Building 1.

Last week, AmeriCann provided a construction update on Building 1 of its Massachusetts Cannabis Center (MCC). The construction of Building 1 of the MCC is 90 percent complete. The project recently received a Temporary Certificate of Occupancy. This means the building is approved for staff to start moving in equipment and fixtures in preparation for final inspections. AmeriCann expects to receive a final Certificate of Occupancy for Building 1 later this summer.

AmeriCann, Inc. (ACAN), closed Monday's trading session at $1.20, up 3.4483%, on 59,376 volume with 85 trades. The average volume for the last 3 months is 40,653 and the stock's 52-week low/high is $0.042100001/$0.230000004.

chart

China Health Industries Holdings, Inc. (CHHE)

The Hot Penny Stocks, OTC Markets, Simply Wall St, Stockhouse, StockEarnings, Market Screener, Zacks, Hot OTC Stocks, Wallmine, InvestorsHub, Marketwired, Proactive Investors, Wallet Investor, YCharts, and GuruFocus reported previously on China Health Industries Holdings, Inc. (CHHE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

China Health Industries Holdings, Inc. is a holding company vertically integrated with the operations in its subsidiaries in the People’s Republic of China (PRC). The Company specializes in research and development (R&D), production, marketing and distribution of hemp derivative products, medicines and health supplement products. China Health Industries Holdings lists on the OTC Markets’ OTCQB. The Company is based in Harbin, China.

In December 2018, the Company announced it completed the strategic transformation from being a traditional health supplement products manufacturer to a hemp derivative products pioneer. Its hemp derivative products have been launched into the Chinese market since May of 2018. This includes Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Hemp Cosmetics.

The Company’s intention is to market much of its product line covering all of China and also overseas countries. As an initial step toward implementing its business plan, China Health Industries strategically transferred its business to production, sales and R&D of Hemp-based products in 2018. It is working to establish sales centers and chain-stores to connect consumers closely with its products.

China Health Industries owns GMP certified plants and facilities. It manufactures 21 CFDA approved medicines and 14 health supplement products covering five kinds of dosage forms. These include soft capsule, hard capsule, tablet, granule, and oral liquid. The Company’s product series encompass hemp derivative foods, hemp derivative medicines, externally used medicines and health foods. These products address important major markets. These include women’s products, geriatric products, children’s products, as well as other important market sectors.

This past May, China Health Industries Holdings announced financial results for its Q3 ended March 31, 2019. Total Revenues increased by $664,269 or 43.18 percent for the three months ended March 31, 2019, versus the same period in 2018. The Company’s Gross Margin increased by $1,137,102 or 203.41 percent for the three months ended March 31, 2019, versus the same period in 2018. Net Income was $767,929 for the three months ended March 31, 2019, versus Net Income of $10,711 for the three months ended March 31, 2018. Net Income per Share was $0.0117 for the three months ended March 31, 2019. Net Income per Share was $0.0002 for the three months ended March 31, 2018.

China Health Industries Holdings, Inc. (CHHE), closed Monday's trading session at $0.75, even for the day on 50 volume. The average volume for the last 3 months is 1,237 and the stock's 52-week low/high is $0.000096/$0.0003.

chart

Flower One Holdings, Inc. (FLOOF)

Invest Tribune, Investing News, Trading View, Dividend Investor, Cash Crop Today, Pot Stock News, Marketbeat, Street Insider, Investor Ideas, Stockwatch, Investors Hangout, Stockhouse, New Cannabis Ventures, and InvestorsHub reported beforehand on Flower One Holdings, Inc. (FLOOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings, Inc. is on the fast track to becoming the leading cannabis cultivator, producer, as well innovator in Nevada. The Company owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms. Furthermore, it owns the established NLV Organics consumer brand of cannabis products. OTCQB-listed, Flower One Holdings is based in Toronto, Ontario.

The Company is converting its 455,000 square-foot greenhouse and production facility for cultivating and processing high-quality cannabis at scale. This facility is the largest in the State of Nevada. Combined, the flagship greenhouse facility and production facility (upon being totally operational) and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products.

The Company is completely licensed for medical marijuana cultivation and production, and also recreational marijuana cultivation and production in Nevada. Flower One currently holds licensing agreements with its Brand Partners - Flyte Concentrates, Rapid-Dose Therapeutics' Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, Grenco Science (G Pen), and The Medicine Cabinet.

Last week, Flower One Holdings announced a long-term licensing agreement with California cannabis-favorite, La Vida Verde (LVV). LVV is the health-centered cannabis brand committed to using high-quality, vegan, organic, gluten-free, and paleo-friendly ingredients to produce cannabis edibles and tinctures. This marks LVV's first out-of-State expansion and entrance into Nevada. The parent company of a holistic line of edible cannabis products, LVV's organic, vegan, non-GMO and gluten-free products have been branded and are available via its three in-house brands: La Vida Verde, Skunk Feather™, and Blank Brand™.

Today, Flower One Holdings officially welcomed Mr. Kellen O'Keefe to the team as Chief Strategy Officer. Mr. O'Keefe hails most recently from MedMen Enterprises, one of America's foremost cannabis retailers and premium brands. As the Senior Vice President of Business Development of MedMen, he was instrumental in capitalizing the business and also sourcing, accessing, as well as executing the company's M&A (Mergers & Acquisitions)) transactions.

Mr. O'Keefe will oversee Flower One Holdings’ market strategies. This includes ongoing investor relations and the growth and development of the Company's Brand Partner program. Additionally, he will lend strategic marketing advice and implement best practices to ensure Flower One continues to be well-positioned in the eyes of the industry, public markets, and investor audiences.

Flower One Holdings, Inc. (FLOOF), closed Monday's trading session at $2.10, off by 2.3256%, on 26,767 volume with 66 trades. The average volume for the last 3 months is 87,499 and the stock's 52-week low/high is $0.912500023/$5.65000009.

chart

Ucore Rare Metals, Inc. (UURAF)

Streetwise Reports, Street Register, Trading View, Marketbeat, Micro Small Cap, Wallet Investor, Northern Miner, and Stockhouse reported previously on Ucore Rare Metals, Inc. (UURAF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Ucore Rare Metals, Inc. engages in the exploration and separation of rare earth elements in The United States and Canada. Ucore is a development-phase company focused on rare metals resources, extraction and beneficiation technologies with near term potential for production, growth and scalability. The Company has a 100 percent ownership stake in Bokan-Dotson Ridge (Bokan). Bokan is the highest grade heavy rare earth project within the U.S. based on NI 43-101 standards. Ucore Rare Metals is headquartered in Nova Scotia, Canada. The Company lists on the OTC Markets Group’s OTCQX.

Ucore’s vision and plan is to transition to become a leading nanotechnology company, which provides mineral separation products and services to the mining and mineral extraction industry. The Company’s vision includes the development of a Strategic Metals Complex in Ketchikan, Alaska and the development of its rare earth minerals property at Bokan Mountain in Alaska.

On March 31, 2014, Ucore announced the unanimous support of the Alaska State Legislature for Senate Bill 99 (2014), which authorized the AIDEA to issue up to USD $145 Million in bonds for the infrastructure and construction costs of the Bokan-Dotson Ridge Rare Earth Project. The Bokan Project is the Company’s primary focus. The Project is 60 km southwest of Ketchikan, Alaska and 140 km northwest of Prince Rupert, British Columbia. It has direct ocean access to the western seaboard and the Pacific Rim.

Pertaining to Ucore Rare Metals’ SuperLig®-One pilot plant project, it has been engineered to accept a Pregnant Leach Solution (PLS). The initial output products are carbonate salts of the critical rare earth elements dysprosium, europium and terbium derived from the Bokan Dotson-Ridge Heavy REE Project in Southeast Alaska.

Concerning the Ray Mountains, Alaska Project, Ucore, by way of a wholly-owned operating subsidiary, holds claims on land selected for its mineral resource potential by the State of Alaska as part of the State’s land entitlement under the 1958 Alaska Statehood Act. Ucore is planning expanded exploration once title transfer is tentatively approved by the federal government.

In June, Ucore Rare Metals commented on the U.S. Department of Commerce's report: A Federal Strategy to Ensure Secure and Reliable Supplies of Critical Minerals. Published June 4, 2019, the Report is a direct response to President Donald J. Trump's Executive Order 13817 (of the same title) issued on December 20, 2017. This wide-ranging Report presents 6 Calls to Action, 24 goals, and 61 recommendations concerning the specific steps that the U.S. Federal Government will take to lessen American dependency on foreign nations for the supply of 35 minerals designated as critical by the Department of Interior in 2018.

The announcement and prioritization are significant for Ucore Rare Metals; 7 of the 8 primary minerals at the Bokan Mountain Complex (BMC) in Southeast Alaska are identified as Critical Minerals under the Report.

Mr. Jim McKenzie, President and Chief Executive Officer of Ucore Rare Metals, said, "Continuing trade tensions between the U.S. and China have resulted in the urgent calls to action and long term goals of this Report. The tensions have also prompted significant recent price gains for minerals that Bokan has in abundance, most notably Heavy REE's such as Dy and Tb. The Bokan deposit is unique in the U.S., with its unusual skew towards these valuable HREE's.

Ucore Rare Metals, Inc. (UURAF), closed Monday's trading session at $0.1686, up 16.1957%, on 507,542 volume with 51 trades. The average volume for the last 3 months is 288,200 and the stock's 52-week low/high is $0.550100028/$1.85000002.

chart

EOS, Inc. (EOSS)

OTC Markets, Barchart, Stockhouse, InvestorsHub, 4-Traders, The Street, Wolf Street, Dividend Investor, Seeking Alpha, Morningstar, MarketWatch, last10k, Stockopedia, Wallet Investor, Real Investment Advice, and Trading View reported earlier on EOS, Inc. (EOSS), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

EOS, Inc. has a broad distribution network of associates with many dealer companies providing health care, beauty care, and environmentally friendly cleaning products in Asia. Since Q1 of 2017, the Company has expanded its marketing channels in China and Southeast Asian countries. Formed in 2015 and OTCQB-listed, EOS is headquartered in Taipei, Taiwan.

The Company previously acquired all of the issued and outstanding shares of Emperor Star International Trade Co. Ltd. (effective May 3, 2017). This is the trading team that plays a vital part in the supply chain of EOS products. EOS acquired Emperor Star trading company in Taipei, Taiwan to strengthen its business and prepare for the challenge of OBOR (One Belt and One Road) development in Malaysia, Indonesia, Thailand, and Cambodia. Emperor Star has been distributing highly unique health and beauty care products and environmentally friendly cleaning products, with first-rate growth in China and Asia.

EOS focuses on the marketing and distribution of skin care products to resellers in Taiwan. It engages in the distribution and marketing of skin care products manufactured by A.C. (USA), Inc. Its products include moisturizers, serums, cleansers, and toners. Products also include exfoliators, acne and oil correctors, facial masks, cleansing devices, and sun care products.

In 2017, Mr. Ben Yang, the chief representative of Asian market, EOS, Inc., signed agency contracts in Nanning City, Guangxi, China, with three owners of new flagship stores launched there. There are four flagship stores set up in China. This includes the first one in Quanzhou. This will help contribute to growing the business of EOS in China. Nanning City is the largest economy of Guangxi province.

On November 30, 2018, EOS signed a contract with A-Best Company and commenced to march toward the worldwide 3C market. A-Best Company is a foremost manufacturer of advanced Piezoelectric Ceramic Speakers.

The collaboration contract was signed by Mr. Yang He-Hsiang, President of EOS, and Mr. Lai Ying-Min, President of A-Best Wire Harness & Components Co., Ltd., at Gloria Prince Hotel in Taipei, Taiwan. The focus of this collaboration is on promoting A-Best Company's patented products, Piezoelectric Ceramic Speakers, and developing more value added products to the international 3C market.

EOS, Inc. (EOSS), closed Monday's trading session at $2.50, up 72.4138%, on 2,080 volume with 17 trades. The average volume for the last 3 months is 75 and the stock's 52-week low/high is $0.000049999/$0.000699999.

chart

Orbital Tracking Corp. (TRKK)

OTCMagic, Stock Commander, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, Stock Preacher, Beacon Equity Research, SuperStockTips, Penny Stock Finder, Penny Stock Craze, MicroCapDaily, SmallCap Network, InvestorSoup, and Shiznit Stocks reported on Orbital Tracking Corp. (TRKK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Orbital Tracking Corp. provides satellite-based tracking, services, and mobile voice and data communications services worldwide, via satellite, to commercial and government users. The Company completed a reverse merger and a subsequent $1.1 million equity capital raise in February of 2015. This created Orbital Tracking Corp., a publically listed organization including the operations of Global Telesat Communications Ltd., a UK corporation (GTCL). OTCQB-listed, Orbital Tracking is headquartered in Aventura, Florida. 

Orbital Tracking (as a newly combined entity) launched as a fully operational Mobile Satellite Solutions (MSS) business. It specializes in services related to the Globalstar satellite constellation. This includes ground station construction, simplex tracking services, and satellite telecommunications voice airtime. The Company operates different e-commerce retail and tracking sites where users around the world can buy satellite hardware and track assets in real-time on mobile devices or personal computers (PCs).  

Orbital Tracking’s subsidiaries, U.S.-based Orbital Satcom Corp. and European Union (EU)-based Global Telesat Communications Ltd., provide around the world distribution of a broad variety of portable satellite voice, data, and tracking solutions. Global Telesat Communications (GTC) is a supplier of mobile voice and data communications services via satellite. GTC provides equipment and airtime for use on all the major satellite networks. This includes Globalstar, Inmarsat, Iridium, and Thuraya, permitting users in remote locations to make phone calls, connect to the internet, and track assets or personnel anywhere globally.

Orbital Tracking further expanded its reach into new markets in 2018 through the opening of its first e-commerce storefront in Australia. Notable orders it received during Q1 2018 in terms of Sales Revenue included the supply of satellite terminals and airtime for use by a disaster preparedness organization and annual renewal of the UK’s Forestry Commission’s 750+ SPOT Gen3 messaging plans.

Recently, Orbital Tracking announced that it was included on Deloitte’s Technology Fast 500™. This is a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy technology companies in North America. Orbital Tracking’s Revenue increased by 148 percent during the period measured.

Orbital Tracking’s Chief Executive Officer, Mr. David Phipps, said, "We are pleased to make our first entry on Deloitte’s Technology Fast 500 and to be amongst just 3 percent of companies recognized in the 2018 winners list in the communications sector.”

Orbital Tracking Corp. (TRKK), closed Monday's trading session at $0.50, up 134.7418%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 622 and the stock's 52-week low/high is $1.29814994/$2.60999989.

chart

Blue Sphere Corp. (BLSP)

DreamTeamNetwork, Hotstocked, Investors Hangout, Biz Journals, Penny Stock General, Stock Shock and Awe, Fast Money Alerts, PennyStocks24, MyBestStockAlerts, OTPicks, PremiereStockAlerts, Dividend Investor, SmallCapVoice, and Infront Analytics reported previously on Blue Sphere Corp. (BLSP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Established in 2007, Blue Sphere Corp. is a worldwide Independent Power Producer (IPP). The Company is working to become an important player in the global waste-to-energy and renewable energy markets. It has a business plan that fits the changing regulatory standards for waste and energy. A clean-technology waste-to-energy producer, Blue Sphere is based in Charlotte, North Carolina. The Company has operations in the U.S,  Israel,  and Europe.

Blue Sphere’s main business model is BOO (Build-Own-Operate) - long-term energy agreements are executed with electric companies in advance of projects. Blue Sphere is performing waste-to-energy projects in the U.S. and Italy.  It is pursuing a strategy to work in association with landfill owners to convert harmful methane gas emissions from landfills into electricity. The process is established on readily available technology already being used in different parts of the U.S. and other areas internationally.

Blue Sphere develops, owns, and operates clean-technology, biogas co-generation, as well as waste-to-energy facilities around the world. It chiefly converts organic waste into electricity. In addition, the Company can produce heat, natural gas and organic by-products through an assortment of technologies.  

Blue Sphere has its Charlotte, North Carolina Waste to Energy Anaerobic Digester 5.2 MW Plant. The Output Production is Electricity and Soil Amendment. In Johnston, Rhode Island, Blue Sphere has its Waste to Energy Anaerobic Digester 3.2 MW Plant. The feedstock is organic waste. The Output Production is also Electricity and Soil Amendment.

The Company has acquired 100 percent of the stock of Agricerere, S.R.L., Agrielektra, S.r.L., Agrisorse, S.r.L. and Gefa, S.r.L.  Individually, each totally operational facility generates one megawatt of electricity per hour, which sells to Gestore del Servizi Energetici GSE, S.p.A., a state owned company that promotes and supports renewable energy sources in Italy, under a Power Purchase Agreement  (PPA) that runs through December 31, 2027.

Recently,  Blue Sphere provided an update on its natural oil generator facility in Udine, Italy. At present, the Company is in the process of completing its planned update of the power generation engine at the Undine facility. As part of the facility upgrade, Blue Sphere purchased a Mitsubishi 4-cycle, water-cooled, turbo-charged inline 6. It can generate Nominal Power of 1050 KwH. This engine upgrade will boost the facility's top-end revenue performance by roughly 2 percent. 

Blue Sphere Corp. (BLSP), closed Monday's trading session at $0.0001, even for the day, on 188,376,656 volume with 69 trades. The average volume for the last 3 months is 9,969,526 and the stock's 52-week low/high is $1.80999994/$3.0999999.

chart

Prism Technologies Group, Inc. (PRZM)

Zacks, Wall Street Journal, TradingView, MarketWatch, and InvestorsHub reported on Prism Technologies Group, Inc. (PRZM),  and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Prism Technologies Group, Inc. is an intellectual property (IP) licensing and technology research & development  (R&D)  company. The Company, by way of its wholly-owned subsidiaries, owns a patent portfolio consisting of nine patent families incorporating 61 issued and six pending patents in the Computer & Network Security, Semiconductors, and Medical Technology arena.

Established in 1995, Prism Technologies Group is the parent company of Prism Technologies, LLC, which is a Nebraska Limited Liability Company (LLC) based in Omaha, Nebraska. Prism Technologies Group has its corporate office in Folsom, California.

The Company previously went by the name Internet Patents Corporation. It changed its name to Prism Technologies Group, Inc. in September of 2015. The Company lists on the OTC Markets Group’s OTCQB.

Prism Technologies Group licenses and enforces a portfolio of patents relating to its technologies. It continues to develop and patent new technologies.

The Company’s dedication is to continuing R&D efforts in a number of fields. Its mission is to continue to develop and invent new technologies in computer and network security, wearable computing, transaction processing,  and healthcare to speed up time to market opportunities for its clients.

Prism Technologies Group’s Executive Team includes Mr. Hussein A. Enan - Chairman, Chief Executive Officer; and Mr. Greg Duman - President, Prism Technologies, LLC and member of Prism Group's Board of Directors. Mr. Duman chairs the Audit Committee.

Prism Technologies Group announced in October of 2017 that it entered into an Asset Purchase Agreement with Amorphous Technologies International (ATI). ATI is a leader in the development of innovative amorphous alloy solutions based on proprietary materials technology. Its solutions deliver value through removing the limits of existing materials technology, which result in high costs throughout the lifecycle of a product.

The Agreement is to acquire certain intellectual property (IP) assets related to unique uses for amorphous metals.  After the close of the transaction, Prism will commercialize the acquired IP assets to create new amorphous metal technology offerings for the consumer electronics, automotive, industrial, and other business sectors.

Prism Technologies Group, Inc. (PRZM), closed Monday's trading session at $0.0689, up 125.9016%, on 5,200 volume with 1 trade. The average volume for the last 3 months is 12,480 and the stock's 52-week low/high is $0.50999999/$4.50.

chart

Tautachrome, Inc. (TTCM)

MarketWatch and InvestorsHub reported on Tautachrome, Inc. (TTCM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Tautachrome, Inc. is an emerging growth enterprise in the developing digital imagery technology sector. It is a developer of software applications for trustable and engageable digital pictures and videos. The Company’s chief priority is developing its branded KlickZie platform. An Internet technology development business, Tautachrome is headquartered in Oro Valley, Arizona and has operations in the United States and Australia. 

The KlickZie platform will turn smartphones into trusted imagers. This means the pictures and videos they capture can be verified as original, untampered,  and un-photoshopped. Additionally, the KlickZie platform creates imagery that is interactive and engageable. 

The KlickZie platform will serve as the world’s first imagery-based social website network. Through clicking or tapping on a KlickZie'd image, users can communicate with the image's author or others presently looking at the image, in an engaging way. 

Basically,  KlickZie is an image verification service for smartphones. It brings trust back to digital imagery. In addition, KlickZie turns the smartphone into a reliable image source. Smartphone users download KlickZie’s free software to take their pictures and videos. 

KlickZie pictures and videos are invisibly marked, stored in the KlickZie cloud, and guaranteed free from manipulation. The cloud will certify the authenticity of any KlickZie picture or video.

Tautachrome also has pioneering patents pending. These include Talk-to-the-Picture social networking and the abovementioned trustable imagery-based interaction. 

Tautachrome is establishing a development team of providers to develop a blockchain based cryptocurrency ecosystem with a cryptotoken designated “KLK”. It will be the currency of the KlickZie community internationally.

This will permit KlickZie users to monetize their pictures and videos. As a result, it will enable the buying, selling, and licensing of KlickZie pictures and videos everywhere.

Recently, Tautachrome announced that it hired the Pryor Cashman law firm in New York to lead its work to register its KLK cryptotoken sale with the Securities and Exchange Commission (SEC). Mr. Ali Panjwani with support from his colleagues Mr. Jeff Alberts and Mr. Mike Campoli is leading the Pryor Cashman work team.

This team has considerable cryptotoken knowledge. In addition, it has significant experience with SEC registration. This includes past employment with the SEC in this area.

Tautachrome Chief Executive Officer, Dr. Jon N Leonard, said, “I have directed the Pryor Cashman team to work with the SEC’s crypto currency task force to ensure that our vision for a KLK cryptotoken-based ecosystem, able to monetize the world’s smartphone imagery becomes a reality, and that it is fully compliant with SEC regulations. We appear to be breaking new ground in this work. But I believe that the social and economic potential of this effort is so great, that every effort is justified.”

Tautachrome, Inc. (TTCM), closed Monday's trading session at $0.0162, up 44.00%, on 166,704,529 volume with 2,716 trades. The average volume for the last 3 months is 49,035,992 and the stock's 52-week low/high is $0.659300029/$2.48749995.

chart

Dais Analytic Corp. (DLYT)

HotOTC, SmallCapVoice, CoolPennyStocks, MadPennyStocks, StockEgg, StockRich, Stockpalooza, Money Morning, Penny Stock Rumble, FeedBlitz, M2 Communications, SmallCap Pulse, BullRally,  PennyInvest, PennyStockVille, and Greenbackers  reported  earlier on Dais Analytic Corp. (DLYT), and  today we are highlighting the Company , here at the QualityStocks Daily Newsletter.  

Dais Analytic Corp sells its industry-changing nanomaterial technology into the global water, air, and energy markets. A commercial nanotechnology materials enterprise, the Company provides nanotechnology-based applications for heating & cooling, water treatment, and energy storage. It is commercializing its unique Aqualyte™ family of nano-structured materials and processes centering on disruptive air, energy, and water applications. Dais Analytic is headquartered in Odessa, Florida.   
  
The uses of the Aqualyte™ family of nano-structured materials and processes include ConsERV™. This is a commercially available engineered energy recovery ventilator (a heating, ventilation, and air conditioning (HVAC) product). 

In addition, the uses include NanoAir™. This is an early beta-stage water-based, no fluorocarbon producing refrigerant cooling cycle.  Uses also include NanoClear™. This is an early beta-stage method for treating contaminated water to provide 1,000 times cleaner potable water.

The NanoClear™ process has consistently shown that Dais Analytic’s novel Aqualyte® material can separate most contaminants from water, realizing almost 'parts per billion' clean product water with little or no fouling of the vital membrane component.

NanoClear™ is a leading-edege water cleaning architecture enabled by the features in the Company’s nanomaterial - Aqualyte™. The NanoClear™ product line is a critical application in purifying contaminated water having high salt content, low pH, or where the requirement for Total Dissolved Solid (TDS) in the product water is 10 or less. 

Furthermore uses include NanoCAP™. Dais indicates that NanoCAP™ holds promise to use the Aqualyte™ family to form a disruptive, non-chemical, energy-storage device (an ultra-capacitor) when completed for use in transportation, renewable energy, and also 'smart grid' configurations.

This past summer, Dais Analytic announced it signed a 7 year, non-exclusive agreement with the Menred Group, Zhejiang province, China, to provide its Aqualyte moisture transfer nanomaterial for use in a newer line of Menred energy recovery ventilators (ERV) to sell into the increasing Chinese heating, ventilation and air conditioning (HVAC) market.

Energy Recovery Ventilators are used in association with HVAC equipment to save capital and operating costs. This is while improving the quality of life for the building's occupants.

High effectiveness ERVs, such as ConsERV™ or Menred Group's new line of ERVs to be built utilizing Dais Analytic's Aqualyte nanomaterial, enable architects and engineers to design buildings with considerable volumes of filtered, preconditioned supply air.

Mr. Brian Johnson Dais Analytic’s Chief Technology Officer, said in July 2017, "Dais' ConsERV™ has long been a leader in this field as established by our Air-Conditioning, Heating and Refrigeration Institute (AHRI) certified performance -- along with other similar ratings from 3rd party rating company's worldwide. Our Aqualyte™ nanomaterial, now in its 4th generation, drives this performance and we are excited about working with Menred to bring a new series of ERVs with Aqualyte to the growing Chinese ERV market."

Dais Analytic Corp. (DLYT), closed Monday's trading session at $0.0016, up 60.00%, on 602,203 volume with 4 trades. The average volume for the last 3 months is 2,941,218 and the stock's 52-week low/high is $2.0999999/$33.7999992.

chart

China ShouGuan Investment Holding Group Corporation (CHSO)

OTC Markets, MarketWatch, InvestorsHub, Morningstar, GuruFocus, and StreetInsider reported on China ShouGuan Investment Holding Group Corporation (CHSO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

China ShouGuan Investment Holding Group Corporation, with equity investment as its core, and operational entities as its foundation, is a large-scale integrated Investment holding Group. The OTCQB-listed Company has expanded its business layout that covers its investment bank business, the new energy industry, the environmental protection and energy-saving industry, the mining industry, the health industry, and also the hi-tech industry and more.
Incorporated in 2010, China ShouGuan Investment Holding Group Corporation is based in Shenzhen, China.

Regarding mining, China ShouGuan is a gold mining exploration, development, and advisory Company in the gold rich zones of Shandong and HeiLongJiang Provinces in the People’s Republic of China (PRC). The Company’s emphasis is acquiring or leasing under-performing mines in major mineral zones. It then finances their expanded exploration and production utilizing industry leading technologies. 

China ShouGuan’s projects include the Dayuan Gold Mine, which covers an area of 0.3475 square kilometers in Longkou city of Shandong; and the mine in the Daxinganling area in Heilongjiang Province in the northeastern part of China. 

China ShouGuan also provides mining technical advisory services. Moreover, the Company provides consulting services in the areas of geological analysis and mine exploration. The range of its mining business encompasses exploration, mining, beneficiation and technical consultation. Its principal business is gold mining, with geological prospecting and technical consultation as supplementary services. 

China ShouGuan Investment Holding Group is diversifying its business. The Company has its Pro-Environment; Eco-Agriculture; Health, and Investment initiatives. Pertaining to Pro-Environment, it entered into the environmental protection field through beginning with sewage sludge treatment and disposal. Relying on its ion fractionation sewage sludge treatment technology, the Company provides integral services for sewage sludge treatment projects. 

Regarding Eco-Agriculture, the agricultural company affiliated to Shouguan Group is one of the first companies to introduce and plant, and also work on product research of the Melaleuca tree in China. Concerning Health, China Shouguan’s commitment is to the development of the health industry, along with setting up funding and concentrating on the development of life sciences, health products, and investing in the health industry. Additionally, the Investment business line of China Shouguan covers industrial investment, financial investment, private equity fund management, investment banking services, and more. 

China ShouGuan Investment Holding Group Corporation (CHSO), closed Monday's trading session at $0.039, up 143.75%, on 777,870 volume with 126 trades. The average volume for the last 3 months is 16,308 and the stock's 52-week low/high is $0.50/$4.23000001.

chart

The QualityStocks Company Corner

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), parent company of Organigram Inc., a leading licensed producer of cannabis, today announced its financial results for its fiscal third quarter ended May 31, 2019. “We continued to report strong sales in our third quarter and now have distribution in all ten provinces,” Organigram CEO Greg Engel said in the news release. The company held a conference call to discuss its Q3 2019 earnings earlier today. Interested parties may access a replay of the call by visiting http://nnw.fm/rm1KP. To view the full press releases, visit http://nnw.fm/TLap2 and http://nnw.fm/1pGI2.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Monday's trading session at $6.10, up 4.6312%, on 2,528,964 volume with 8,311 trades. The average volume for the last 3 months is 1,058,943 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was highlighted today in a publication from Investorideas.com, examining how hemp and solar stocks releases a sector snapshot reporting on green investing trends from renewable energy to cannabis and how millennial investors are driving this movement.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Monday's trading session at $2.4146, up 0.608333%, on 313,423 volume with 528 trades. The average volume for the last 3 months is 561,335 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis, Inc. (TSX.V: VIVO) (OTCQX: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. A marijuana education and advocacy group in Arkansas has announced that it plans to file two petitions with the state government so that recreational marijuana can be legalized through a ballot measure. The second petition covers the expungement of marijuana-related convictions.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Monday's trading session at $0.376131, up 2.7119%, on 89,113 volume with 53 trades. The average volume for the last 3 months is 228,277 and the stock's 52-week low/high is $0.330000013/$1.52999997.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical services company, is focused on three key niches in the health care market, a $4 trillion industry that’s expected to grow as the general population ages. TRXD offers a unique combination of a web-based purchasing platform for transactions between independent pharmacists and drug distributors; a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services.

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed Monday's trading session at $0.60, even for the day, on 1,304 volume. The average volume for the last 3 months is 2,890 and the stock's 52-week low/high is $0.230000004/$0.75.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands LP (OTC: VPRB) is a technology holding company based in Fort Lauderdale, Florida, that continues to drive scale across diverse high-growth verticals. With its award-winning design and diligent product innovation, VPR Brands offers investors a gateway to the vape products marketplace. Also today, NetworkNewsWire released a report on the company detailing how VPRB recently announced that its HONEYSTICK brand vaporizers are now available through JUUL brand master distributor HS Wholesale, a leading wholesale distributor for vape stores and smoke and head shops. Additionally, the company was featured today in the 420 with CNW by CannabisNewsWire. A marijuana education and advocacy group in Arkansas has announced that it plans to file two petitions with the state government so that recreational marijuana can be legalized through a ballot measure. The second petition covers the expungement of marijuana-related convictions.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Monday's trading session at $0.043, even for the day, on 2,100 volume with 3 trades. The average volume for the last 3 months is 66,608 and the stock's 52-week low/high is $0.026/$0.119999997.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), manufacturer and marketer of cannabis food products, was identified as a ‘premier edibles brand to watch’ in a bullish analysis by Technical420 that cites the company’s growth into Nevada from its California base (http://nnw.fm/Fc7SD).

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Monday's trading session at $2.6233, off by 1.01%, on 52,942 volume with 87 trades. The average volume for the last 3 months is 64,666 and the stock's 52-week low/high is $3.01999998/$7.96999979.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) was highlighted today among Virtual Investor Conferences participating companies due to having given a recent presentation at the July 11 life sciences conference, which is now available to everyone http://ibn.fm/yst1J.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Monday's trading session at $0.7863, off by 4.6909%, on 87,171 volume with 85 trades. The average volume for the last 3 months is 84,853 and the stock's 52-week low/high is $0.75/$2.24.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, reported a 66.4 percent rise in revenues to $770,635 for the 12 months ended March 31, as compared to $463,108 for the same period in 2018 (http://nnw.fm/sXqz2).

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Monday's trading session at $0.7541, off by 3.3205%, on 25,218 volume with 26 trades. The average volume for the last 3 months is 57,374 and the stock's 52-week low/high is $0.300999999/$2.45000004.

Recent News

chart

MustGrow Biologics Corp. (CSE: MGRO)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp..

MustGrow Biologics Corp. (CSE: MGRO), an agricultural biotech company, has entered into a partnership with Triangle Plant Sciences (“TPS”), a division of Verdesian Life Sciences of Cary, North Carolina. Under the agreement, MustGrow will have exclusive Canadian and global access to TP-1000, TPS’s first product in a suite of researched hydroponic technology offerings. To view the full press release, visit http://nnw.fm/VJOu0.

MustGrow Biologics (CSE: MGRO) is an agricultural biotech company focused on developing and commercializing its patented technology that is a natural biopesticide and biofertilizer for use as a fertilizer, nematicide, pesticide and fungicide. MustGrow’s novel and proprietary solutions utilize organic components refined from mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests such as nematodes. The company’s technology provides an all-natural, effective, safe and easy-to-use solution for farmers seeking to raise healthy crops without the use of pesticides.

Nematodes, or microscopic worms, are the most numerous multicellular animals on earth. A handful of soil will contain thousands of nematodes, many of which are parasites of insects, plants or animals. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients?(http://nnw.fm/Qkz21).?For the past 50 years,?nematodes have been controlled using chemical nematicides, but the Environmental Protection Agency now restricts or bans many of the chemical?formulations.

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The American Phytopathological Society (http://nnw.fm/3HGuT), an international nonprofit scientific organization dedicated to the study and control of plant diseases, estimates that plant-pathogenic nematodes are responsible for 14 percent of crop losses worldwide.

MustGrow’s technology refines mustard seeds to concentrate the plant’s natural organic compounds that form Allyl isothiocyanate (“AITC”), which serves the plant as a natural defense system against pests and diseases. As a result, MustGrow’s novel product offers first-class performance, is 100 percent natural, and its fertilizer product is listed for organic use by the Organic Materials Review Institute (“OMRI”) under specifications set by the USDA’s National Organic Program.

MustGrow’s initial technology was a granular pre-plant soil biofumigant and biofertilizer containing the active ingredient AITC, a proven nematicide, fungicide and fertilizer. The company has completed 110 independent third-party field trials on fruit and vegetable crops. As a biofertilizer, MustGrow’s product is registered with Health Canada and the EPA in all U.S. states as OMRI-certified. It is also registered for use as a biopesticide by the EPA in key fruit and vegetable growing U.S. states (except California) and with Health Canada. MustGrow is finalizing a new liquid delivery platform with increased concentration of the same active ingredient (AITC) that can be applied through drip lines to meet the demands of today’s growers.

Results of tests completed to date show that MustGrow continues to provide innovative solutions with broad based applications within agriculture. Validated field trial results include:

  • 100 percent control of root-knot nematodes in strawberry crops as compared to methyl bromide
  • 55 percent tomato crop yield increase
  • 95 percent control of Pythium root rot in lettuce fields
  • 70 percent reduction in Verticillium root severity in cucumbers
  • Market Opportunity

Market Opportunity??

MustGrow is also testing the potential application of its technology to the cannabis industry, which is projected to grow to nearly $22 billion in the U.S. by 2020. While there are no uniform guidelines for pesticide use in the cannabis industry, state-by-state regulations in the U.S. do exist which has led to instances of pesticide-tainted cannabis showing up in tested products, leading to recalls and threats of lawsuits. Health Canada recently published regulations for mandatory testing for pesticides in cannabis that are now in effect for all growers.?MustGrow’s?potential application for cannabis production shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia, and botrytis (gray mold) that affect the cannabis plant. Cannabis consumers are increasingly demanding organic products free from chemicals and have shown they are willing to pay a premium for high-quality organic cannabis. MustGrow is currently running cannabis soil trials and is seeking Health Canada approval for use of its product on cannabis.?

Global crop protection is a multibillion-dollar market that is expected to surge over the next five years. Sales of nematicides are set to grow by 33 percent to $1.43 billion by 2022, while biopesticides are projected to leap by 94 percent to an estimated?$9.5 billion by 2022. MustGrow is targeting the global nematicide industry with products that include an innovative pre-plant soil treatment. Solutions for the global biopesticide industry include seed treatment technologies, fungicides and nematicides.??

MustGrow’s groundbreaking technologies use novel plant compounds to provide superior crop protection naturally.

Management Team

President and CEO Corey Giasson is an entrepreneur with more than 20 years in the agriculture, potash, oil and gas, mining and real estate industries.? Mr. Giasson co-founded Rallyemont Energy Inc., a heavy oil company that successfully identified 140 million barrels of recoverable heavy oil, that was sold in 2013 to Husky Energy. He holds an MBA and bachelor’s degree in agricultural economics from the University of Saskatchewan.

Chairman Brad Munro has 20-plus years as a vice president/investments, with a national venture capital firm where he sourced, invested and managed the activity of over 30 companies and invested $150 million. He has served as a director of over 20 public companies and a greater number of private enterprises. Munro is currently director of Secure Energy Services.

COO Colin Betsky is the previous vice president/BioAg at Novozymes, where he was responsible for the company’s BioAg business worldwide. He holds a bachelor’s degree in agriculture from the University of Saskatchewan and has more than 20 years of experience in agricultural chemicals and biologics.

Director Tom Flow is the founder and current president of The Flowr Corporation (TSX.V: FLWR) and Licensed Producer of cannabis in Canada. He founded and built MedReleaf, Canada’s most profitable Licensed Producer which was later acquired by Aurora Cannabis?(TSX: ACB) (NYSE: ACB) for $3.2 billion. Flow is widely recognized for his leadership and expertise in building and operating cannabis cultivation facilities.

Director Matt Kowalski has a tremendous amount of experience in the fruit and vegetable and biologics industries. Under his leadership at Natural Industries, a business focused on biological pest control, the company was awarded five EPA registrations: three biofungicides, a bionematicide, and a bioinsecticide. In November 2012, Kowalski led the strategic sale of Natural Industries to Novozymes BioAg. He is the principal owner of Stronghold Keep Inc., an investment corporation.

CFO Todd Lahti has extensive experience evaluating and managing start-up companies in the biotechnology, agricultural and oil and gas sectors, working directly on financing transactions, mergers and acquisitions, corporate strategy, business development, technology transfer and operations set up. He is a Chartered Financial Analyst and a Chartered Professional Accountant.

MustGrow Biologics Corp. (CSE: MGRO), closed Monday's trading session at $0.30, off by 6.25%, on 15,624 volume with 11 trades. The average volume for the last 3 months is 292,407 and the stock's 52-week low/high is $0.275000005/$0.699999988.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Technology and investment company SinglePoint Inc. (OTCQB: SING) will launch American Premium Water Corporation’s (OTC: HIPH) Lynks CBD Pet Water through its SingleSeed subsidiary (www.SingleSeed.com). According to the update, Lynks CBD Pet Water is a joint venture with LinkRes Pets (OTC: LRSV), and the product is expected to launch in early August. Also today, the company was highlighted in a publication from Investorideas.com, examining how hemp and solar stocks releases a sector snapshot reporting on green investing trends from renewable energy to cannabis and how millennial investors are driving this movement.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Monday's trading session at $0.0161, off by 5.2941%, on 6,311,737 volume with 208 trades. The average volume for the last 3 months is 5,955,416 and the stock's 52-week low/high is $0.009999999/$0.0447.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical™ therapeutic devices, today announces the appointment of Peter Novak, M.D., Ph.D., to its Scientific Advisory Board. Endonovo CEO Alan Collier stated, “The Endonovo team is delighted to welcome Dr. Novak to the Scientific Board. Peter’s experience will add significant value to our oversight as we transition to and advance our differentiated development programs in Electroceuticals™.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Monday's trading session at $0.014, off by 2.7778%, on 3,222,761 volume with 65 trades. The average volume for the last 3 months is 5,968,422 and the stock's 52-week low/high is $0.008999999/$0.066100001.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions Inc. (OTC: DVLP) has strategically integrated all functioning entities under one management roof (http://nnw.fm/t1Y0g). This move is expected to add more structure to the company, as all divisions will be under the supervision of a central organization, leading to better growth and higher returns on investment. DVLP CEO Stavros Triant stated that all brands under DVLP will function in collaboration with each other, realizing the potential of every department to its fullest.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset, WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed Monday's trading session at $0.0104, off by 3.2558%, on 1,911,268 volume with 50 trades. The average volume for the last 3 months is 3,220,647 and the stock's 52-week low/high is $0.0081/$0.14.

Recent News

chart

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF).

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF), an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements' expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company.

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company "maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S."

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree's working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed Monday's trading session at $0.2242, up 10.2804%, on 85,180 volume with 33 trades. The average volume for the last 3 months is 113,770 and the stock's 52-week low/high is $0.189999997/$0.605000019.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed Monday's trading session at $0.175, up 16.6667%, on 133,677 volume with 22 trades. The average volume for the last 3 months is 16,159 and the stock's 52-week low/high is $0.1026/$0.3944.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.